By Fineline Cube 
RemeGen Ltd. (HKG: 9995) has announced that China’s National Medical Products Administration (NMPA) has approved a new indication for its flagship antibody-drug conjugate (ADC), disitamab vedotin (RC48). The drug is now approved in combination with toripalimab for the first-line treatment of locally advanced or metastatic urothelial carcinoma (UC) in patients whose tumors express HER2 (IHC 1+, 2+, or 3+). This landmark approval establishes disitamab vedotin as the world’s first HER2-targeting ADC approved for this specific first-line setting.
Approval Details & Significance
| Feature | Detail |
|---|---|
| Drug | Disitamab Vedotin (RC48) |
| New Indication | First-line treatment of HER2-expressing (IHC 1+/2+/3+) locally advanced or metastatic urothelial carcinoma |
| Regimen | In combination with toripalimab (anti-PD-1) |
| Key Milestone | World’s first HER2-ADC approval for first-line advanced UC |
| HER2 Expression Threshold | Broadly defined (IHC 1+ and above), significantly expanding the treatable patient population |
Product Profile & Commercial History
- Pioneering Asset: Disitamab vedotin is recognized as China’s first home-grown ADC to reach the market.
- Established Track Record: Since its initial approval in 2021, it has secured multiple NMPA nods, including for third-line gastric cancer, second-line UC, and both second-line and first-line breast cancer.
- Expanding Reach: This latest approval further cements its position as a versatile and foundational HER2-targeting therapy across multiple solid tumor types in China.
Strategic Implications
- Paradigm Shift in UC: By moving into the first-line setting, disitamab vedotin addresses a much larger patient pool and sets a new standard of care for HER2-expressing UC, a population previously lacking targeted options at treatment initiation.
- Broad HER2 Definition: The inclusion of IHC 1+ patients is a strategic masterstroke, as it captures a far greater proportion of the UC patient population than traditional HER2-positive definitions (typically IHC 3+ or FISH+), dramatically increasing the drug’s market potential.
- Combination Synergy: The pairing with toripalimab, a leading Chinese PD-1 inhibitor, leverages a dual mechanism of action—targeted cytotoxicity plus immune checkpoint blockade—to potentially deliver superior outcomes.
- Global Leadership: This “world’s first” designation not only validates RemeGen’s innovation but also positions the company as a global leader in the rapidly evolving ADC field, particularly in novel indications and target populations.
Market Context
- Competitive ADC Landscape: The race to expand ADCs into new indications and lower lines of therapy is intense. RemeGen’s success in securing this first-in-class approval provides a significant competitive moat in the lucrative UC market.
- Chinese Biotech Ascendancy: This achievement underscores the capability of Chinese biopharma firms like RemeGen to not only develop but also pioneer novel therapeutic approaches on the global stage.
- Commercial Upside: Moving to first-line treatment is the single most impactful event for a drug’s commercial trajectory, and this approval is expected to be a major revenue driver for RemeGen.
Forward-Looking Statements
This brief reports on a marketing approval from the NMPA. Commercial success is subject to market adoption, pricing, and reimbursement. The safety and efficacy in this new indication are based on clinical trial data submitted to the NMPA.-Fineline Info & Tech